Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
| ▸ | CTSS | P25774 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318684 | 0.86 | CTSS (0.65) | ALDH1A1KAT6AKMT2AGAACTSS | |
| SCHEMBL6848743 | 0.86 | KAT6A (0.63) | ALDH1A1KAT6ACTSSCYP19A1L3MBTL1 | |
| SCHEMBL8954769 | 0.86 | KAT6A (0.63) | ALDH1A1KAT6AKMT2AGAACTSS | |
| SCHEMBL6792532 | 0.84 | ALDH1A1 (0.84) | ALDH1A1KAT6AGAACYP19A1KDM4E | |
| Hydrochloric Acid SCHEMBL27487670 | 0.84 | KAT6A (0.61) | ALDH1A1KAT6ACTSSCYP19A1L3MBTL1 | |
| SCHEMBL1771503 | 0.84 | CTSS (0.67) | ALDH1A1KAT6AMMP1MMP12CTSS | |
| SCHEMBL3905853 | 0.84 | APEX1 (0.57) | ALDH1A1KAT6AKMT2AMMP1GAA | |
| SCHEMBL8425825 | 0.83 | MAPT (0.60) | ALDH1A1KAT6ACTSSAPEX1 | |
| SCHEMBL6792727 | 0.82 | ALDH1A1 (1.00) | ALDH1A1KAT6AGAAKDM4E | |
| SCHEMBL14045828 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KAT6AKMT2ACTSSCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| WO-2004067522-A1 | AZAPHENYLALANINE DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | LEK PHARMACEUTICALS D.D. (SI) | 2004-08-12 | — | — | WO | disclosed |
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| EP-0772590-B1 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-5714485-A | Piperidine and hexahydropyridazine thrombin inhibitors | MERCK & CO., INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0809650-A1 | SERINE PROTEASE INHIBITORS | ELLERMAN PHARMACEUTICALS LIMITED (GB) | 1997-12-03 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996038470-A1 | IMIDAZO[1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996025427-A1 | SERINE PROTEASE INHIBITORS | ELLERMAN PHARMACEUTICALS LIMITED (GB) | 1996-08-22 | — | — | WO | disclosed |
| US-5510369-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
| US-4977168-A | Derivatives of the N α-arylsulphonylaminoacyl-p-amidinophenyl-alaninamides, and their use as medicaments | SANOFI (FR) | 1990-12-11 | — | — | US | disclosed |
| EP-0236163-B1 | DERIVATIVES OF N-ALPHA-SUBSTITUTED N-ALPHA-ARYLSULFONYLAMINOACYL P-AMIDINOPHENYLALANINAMIDES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THEIR INTERMEDIATES | SANOFI (FR) | 1990-10-03 | — | — | EP | disclosed |
| EP-0236163-A1 | Derivatives of N-alpha-substituted N-alpha-arylsulfonylaminoacyl p-amidinophenylalaninamides, their preparation, their use as medicaments and their intermediates | SANOFI (FR) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | ALDH1A1 1423/4885KAT6A 4118/4885KMT2A 1699/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ALDH1A1 170/4885KAT6A 2810/4885KMT2A 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.